These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Agranulocytosis and fever seven weeks after starting abacavir. Sankatsing SU; Prins JM AIDS; 2001 Dec; 15(18):2464-5. PubMed ID: 11774836 [No Abstract] [Full Text] [Related]
3. Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative. Chen SJ; Yang SP; Hung CC; Fung CP AIDS; 2010 May; 24(8):1238-9. PubMed ID: 20421748 [No Abstract] [Full Text] [Related]
4. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. Escaut L; Liotier JY; Albengres E; Cheminot N; Vittecoq D AIDS; 1999 Jul; 13(11):1419-20. PubMed ID: 10449301 [No Abstract] [Full Text] [Related]
5. Unusual clinical presentation of hypersensitivity reaction to abacavir. Aquilina C; Mularczyk M; Lucas F; Viraben R AIDS; 2003 Nov; 17(16):2403-4. PubMed ID: 14571198 [No Abstract] [Full Text] [Related]
6. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients. Bellagamba R; Tommasi C; De Marco M; Narciso P J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915 [No Abstract] [Full Text] [Related]
9. Abacavir hypersensitivity. Vandekerckhove L; Blot S; Vogelaers D N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052 [No Abstract] [Full Text] [Related]
10. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. Waters LJ; Mandalia S; Gazzard B; Nelson M AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891 [TBL] [Abstract][Full Text] [Related]
11. 1592 (abacavir): do not rechallenge after hypersensitivity reaction. James JS AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916 [TBL] [Abstract][Full Text] [Related]
12. Severe hypersensitivity reactions following reintroduction of abacavir. AIDS Read; 2000 Sep; 10(9):525. PubMed ID: 11019447 [No Abstract] [Full Text] [Related]
13. Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients? Brothers C; Cutrell A; Scott T; Hernandez J; Moult A Int J Clin Pract; 2006 May; 60(5):611-2; author reply 612. PubMed ID: 16700867 [No Abstract] [Full Text] [Related]
14. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. Shapiro M; Ward KM; Stern JJ AIDS Read; 2001 Apr; 11(4):222-6. PubMed ID: 11392679 [TBL] [Abstract][Full Text] [Related]
15. Understanding drug hypersensitivity: what to look for when prescribing abacavir. Hetherington S AIDS Read; 2001 Dec; 11(12):620-2. PubMed ID: 11806176 [TBL] [Abstract][Full Text] [Related]
16. Abacavir hypersensitivity. Abel S; Paturel L; Cabié A N Engl J Med; 2008 Jun; 358(23):2515; author reply 2515-6. PubMed ID: 18536095 [No Abstract] [Full Text] [Related]
17. How do abacavir and efavirenz differ in pharmacokinetics and toxicity? Edmunds-Ogbuokiri J Fac Notes (New Orleans La); 1999; 11(3):1-4. PubMed ID: 11810867 [No Abstract] [Full Text] [Related]
18. Editorial comment: the challenge of prescribing abacavir. Ball SC AIDS Read; 2001 Dec; 11(12):621. PubMed ID: 11806177 [No Abstract] [Full Text] [Related]
19. Labeling changes for abacavir. AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055 [No Abstract] [Full Text] [Related]
20. Screening for abacavir hypersensitivity. Deresinski S AIDS Alert; 2007 Dec; 22(12):140-1. PubMed ID: 18411482 [No Abstract] [Full Text] [Related] [Next] [New Search]